Response and Toxicity to Topotecan in Sensitive Ovarian Cancer Cases with Small Residual Disease after First-Line Treatment with Carboplatinum and Paclitaxel

By Bolis G.   Scarfone G.   Tateo S.   Mangili G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 13-15

Elsevier

Access to resources Recommend Favorite

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

By Morgan Robert   Synold Timothy   Mamelak Adam   Lim Dean   Al-Kadhimi Zaid   Twardowski Przemyslaw   Leong Lucille   Chow Warren   Margolin Kim   Shibata Stephen   Somlo George   Yen Yun   Frankel Paul   Doroshow James  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 927-933

Springer Publishing Company

Access to resources Recommend Favorite

Treatment for Fertility and Risk of Ovarian Tumors of Borderline Malignancy

By Parazzini F.   Negri E.   La Vecchia C.   Moroni S.   Polatti A.   Chiaffarino F.   Surace M.   Ricci E.  

Gynecologic Oncology, Vol. 68, Iss. 3, 1998-03 ,pp. : 226-228

Elsevier

Access to resources Recommend Favorite

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

By Donato M.L.   Gershenson D.M.   Wharton J.T.   Ippoliti C.M.   Aleman A.S.   Bodurka-Bevers D.   Bevers M.W.   Burke T.W.   Levenback C.F.   Wolf J.K.   Freedman R.S.   Bast R.C.   Gajewski J.L.   Champlin R.E.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 420-426

Elsevier

Access to resources Recommend Favorite